Forschungszentrum für Immuntherapie (FZI)
Forschungsschwerpunkt / Johannes Gutenberg-Universität Mainz
Lang, Franziska; Sorn, Patrick; Schroers, Barbara et al.
Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidatesISCIENCE. Bd. 26. H. 11. 2023
Ringen, Julia; Schaller, Theresa; Fischer, Berenice et al.
MYELOID CELL-DERIVED REACTIVE OXYGEN SPECIES FROM LESIONAL SKIN CONTRIBUTE TO VASCULAR INFLAMMATION IN EXPERIMENTAL PSORIASISFREE RADICAL BIOLOGY AND MEDICINE. Bd. 201. 2023 S. 7-7
Bueno, Diones; Dey, Partha Narayan; Schacht, Teresa et al.
NECAB2 is an endosomal protein important for striatal functionFREE RADICAL BIOLOGY AND MEDICINE. Bd. 208. 2023 S. 643-656
Bersano, A.; Engele, J.; Schafer, M. K. E.
Neuroinflammation and Brain DiseaseBMC NEUROLOGY. Bd. 23. H. 1. 2023
Schlegelmilch, Anna-Lena; Schillner, Miriam; Zipp, Frauke et al.
Neuronal intracellular calcium storage release upon direct T-cell-neuron interactionMULTIPLE SCLEROSIS JOURNAL. Bd. 29. 2023 S. 497-498
Giampaolo, Sabrina; Chiarolla, Cristina M.; Knoepper, Konrad et al.
NFATc1 induction by an intronic enhancer restricts NKT yδ cell formationISCIENCE. Bd. 26. H. 3. 2023
Marinovic, Sonja; Lenartic, Maja; Mladenic, Karlo et al.
NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosisSCIENCE IMMUNOLOGY. Bd. 8. H. 87. 2023
Marinovic, Sonja; Lenartic, Maja; Mladenic, Karlo et al.
NKG2D-mediated immunosensing of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosisEUROPEAN JOURNAL OF IMMUNOLOGY. Bd. 53. 2023 S. 17-17
Hartmann, Ann-Kathrin; Bartneck, Joschka; Pielenhofer, Jonas et al.
Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejectionFRONTIERS IN IMMUNOLOGY. Bd. 14. 2023
Sonneveld, Pieter; Chanan-Khan, Asher; Weisel, Katja et al.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III TrialJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 8. 2023 S. 1600-+